Header Logo

Connection

Robert Wild to Polycystic Ovary Syndrome

Back to Details
This is a "connection" page, showing publications Robert Wild has written about Polycystic Ovary Syndrome.
Robert Wild
Connection Strength
6.548
Polycystic Ovary Syndrome
  1. A Possible Screening Marker for Cardiovascular Disease in Polycystic Ovary Syndrome. J Womens Health (Larchmt). 2022 06; 31(6):751-752.
    View in: PubMed
    Score: 0.765
  2. The natural history of polycystic ovary syndrome: commentary on a longitudinal study evaluating changes in phenotype with age. Fertil Steril. 2022 05; 117(5):1067-1068.
    View in: PubMed
    Score: 0.762
  3. Metformin, rosiglitazone, or both for obese women with polycystic ovary syndrome? Fertil Steril. 2020 01; 113(1):87-88.
    View in: PubMed
    Score: 0.649
  4. Dyslipidemia in PCOS. Steroids. 2012 Mar 10; 77(4):295-9.
    View in: PubMed
    Score: 0.371
  5. Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2012 Jan; 97(1):225-30.e2.
    View in: PubMed
    Score: 0.370
  6. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011 Mar 01; 95(3):1073-9.e1-11.
    View in: PubMed
    Score: 0.349
  7. Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. Obstet Gynecol. 2011 Jan; 117(1):145-152.
    View in: PubMed
    Score: 0.348
  8. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010 May; 95(5):2038-49.
    View in: PubMed
    Score: 0.330
  9. Characterizing cardiovascular risk in women with polycystic ovary syndrome: more than the sum of its parts? Semin Reprod Med. 2009 Jul; 27(4):299-305.
    View in: PubMed
    Score: 0.312
  10. Pioglitazone and metformin for increased small low-density lipoprotein in polycystic ovary syndrome: counterpoint. Am J Obstet Gynecol. 2008 Jan; 198(1):4-6.
    View in: PubMed
    Score: 0.282
  11. Polycystic ovarian syndrome: an evidence-based approach to evaluation and management of diabetes and cardiovascular risks for today's clinician. Clin Obstet Gynecol. 2007 Mar; 50(1):226-43.
    View in: PubMed
    Score: 0.266
  12. Ferriman Gallwey self-scoring I: performance assessment in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Jul; 90(7):4112-4.
    View in: PubMed
    Score: 0.234
  13. Long-term health consequences of PCOS. Hum Reprod Update. 2002 May-Jun; 8(3):231-41.
    View in: PubMed
    Score: 0.191
  14. A personalized medicine approach to ovulation induction/ovarian stimulation: development of a predictive model and online calculator from level-I evidence. Fertil Steril. 2022 02; 117(2):408-418.
    View in: PubMed
    Score: 0.187
  15. Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol. 2002 Jan; 186(1):35-43.
    View in: PubMed
    Score: 0.186
  16. Metabolic syndrome in obesity: treatment success and adverse pregnancy outcomes with ovulation induction in polycystic ovary syndrome. Am J Obstet Gynecol. 2021 09; 225(3):280.e1-280.e11.
    View in: PubMed
    Score: 0.177
  17. Metabolic aspects of polycystic ovary syndrome. Semin Reprod Endocrinol. 1997 May; 15(2):105-10.
    View in: PubMed
    Score: 0.135
  18. Hyperandrogenism in the adolescent. Obstet Gynecol Clin North Am. 1992 Mar; 19(1):71-89.
    View in: PubMed
    Score: 0.094
  19. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012 Jan; 97(1):28-38.e25.
    View in: PubMed
    Score: 0.093
  20. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012 Mar-Apr; 18(2):112-26.
    View in: PubMed
    Score: 0.092
  21. Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas heart study. Clin Endocrinol (Oxf). 2011 Jan; 74(1):89-96.
    View in: PubMed
    Score: 0.087
  22. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010 Jul-Aug; 16(4):347-63.
    View in: PubMed
    Score: 0.082
  23. The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome. Am J Obstet Gynecol. 1988 Aug; 159(2):423-7.
    View in: PubMed
    Score: 0.073
  24. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985 Nov; 61(5):946-51.
    View in: PubMed
    Score: 0.061
  25. Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med. 1995 Jan 16; 98(1A):27S-32S.
    View in: PubMed
    Score: 0.029
  26. Evidence of heterogeneous mechanisms in lipoprotein lipid alterations in hyperandrogenic women. Am J Obstet Gynecol. 1990 Dec; 163(6 Pt 1):1998-2005.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.